Log in

NASDAQ:GRTS - Gritstone Oncology Stock Price, Forecast & News

-0.63 (-10.33 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $5.47
50-Day Range
MA: $8.07
52-Week Range
Now: $5.47
Volume98,808 shs
Average Volume188,112 shs
Market Capitalization$202.28 million
P/E RatioN/A
Dividend YieldN/A
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Read More
Gritstone Oncology logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:GRTS



Sales & Book Value

Annual Sales$4.36 million
Book Value$3.75 per share


Net Income$-94,430,000.00
Net Margins-2,163.41%


Market Cap$202.28 million
Next Earnings Date5/11/2020 (Estimated)
OptionableNot Optionable

Receive GRTS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRTS and its competitors with MarketBeat's FREE daily newsletter.

Gritstone Oncology (NASDAQ:GRTS) Frequently Asked Questions

How has Gritstone Oncology's stock been impacted by COVID-19 (Coronavirus)?

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GRTS shares have decreased by 18.0% and is now trading at $5.47. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Gritstone Oncology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gritstone Oncology.

When is Gritstone Oncology's next earnings date?

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Monday, May 11th 2020. View our earnings forecast for Gritstone Oncology.

How were Gritstone Oncology's earnings last quarter?

Gritstone Oncology Inc (NASDAQ:GRTS) announced its quarterly earnings results on Wednesday, March, 11th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.08. The company had revenue of $0.88 million for the quarter, compared to analysts' expectations of $1.20 million. Gritstone Oncology had a negative net margin of 2,163.41% and a negative return on equity of 62.40%. View Gritstone Oncology's earnings history.

What price target have analysts set for GRTS?

3 brokers have issued 12 month target prices for Gritstone Oncology's shares. Their forecasts range from $17.00 to $17.00. On average, they anticipate Gritstone Oncology's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 210.8% from the stock's current price. View analysts' price targets for Gritstone Oncology.

What are Wall Street analysts saying about Gritstone Oncology stock?

Here are some recent quotes from research analysts about Gritstone Oncology stock:
  • 1. According to Zacks Investment Research, "Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors. " (10/15/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of GRTS and our 12-month price target of $17.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected GRANITE-001 and SLATE-001 revenues through 2030, assuming a 12.5% discount rate and 3% terminal growth rate." (4/1/2019)

Has Gritstone Oncology been receiving favorable news coverage?

Headlines about GRTS stock have been trending positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gritstone Oncology earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutGritstone Oncology.

Are investors shorting Gritstone Oncology?

Gritstone Oncology saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,170,000 shares, a decrease of 8.1% from the February 27th total of 3,450,000 shares. Based on an average daily volume of 155,800 shares, the short-interest ratio is currently 20.3 days. Currently, 24.8% of the company's stock are sold short. View Gritstone Oncology's Current Options Chain.

Who are some of Gritstone Oncology's key competitors?

What other stocks do shareholders of Gritstone Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include Crispr Therapeutics (CRSP), Clovis Oncology (CLVS), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Amarin (AMRN), AT&T (T), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), Micron Technology (MU) and Nektar Therapeutics (NKTR).

Who are Gritstone Oncology's key executives?

Gritstone Oncology's management team includes the following people:
  • Dr. Andrew R. Allen, Co-Founder, Pres, CEO & Director (Age 52)
  • Dr. Karin Jooss, Exec. VP of Research & Chief Scientific Officer (Age 54)
  • Prof. Raphaël F. Rousseau M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 50)
  • Mr. Jean-Marc Bellemin M.B.A., Exec. VP of Fin. & CFO (Age 47)
  • Dr. Roman Yelensky, Exec. VP & CTO (Age 40)

When did Gritstone Oncology IPO?

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

What is Gritstone Oncology's stock symbol?

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Who are Gritstone Oncology's major shareholders?

Gritstone Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Casdin Capital LLC (6.03%), State Street Corp (1.31%), UBS Asset Management Americas Inc. (1.08%), Victory Capital Management Inc. (1.03%) and Victory Capital Management Inc. (1.02%). Company insiders that own Gritstone Oncology stock include Nicholas Simon and Raphael Rousseau. View institutional ownership trends for Gritstone Oncology.

Which institutional investors are selling Gritstone Oncology stock?

GRTS stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Oxford Asset Management LLP, Victory Capital Management Inc., Victory Capital Management Inc., New York State Common Retirement Fund, and UBS Asset Management Americas Inc.. View insider buying and selling activity for Gritstone Oncology.

Which institutional investors are buying Gritstone Oncology stock?

GRTS stock was purchased by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Captrust Financial Advisors, State Street Corp, California Public Employees Retirement System, Geode Capital Management LLC, Goldman Sachs Group Inc., Barclays PLC, and ProShare Advisors LLC. View insider buying and selling activity for Gritstone Oncology.

How do I buy shares of Gritstone Oncology?

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gritstone Oncology's stock price today?

One share of GRTS stock can currently be purchased for approximately $5.47.

How big of a company is Gritstone Oncology?

Gritstone Oncology has a market capitalization of $202.28 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis. Gritstone Oncology employs 113 workers across the globe. View additional information about Gritstone Oncology.

What is Gritstone Oncology's official website?

The official website for Gritstone Oncology is http://www.gritstoneoncology.com/.

How can I contact Gritstone Oncology?

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 300, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]

MarketBeat Community Rating for Gritstone Oncology (NASDAQ GRTS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  105 (Thanks for Voting!)
Underperform Votes:  91 (Thanks for Voting!)
Total Votes:  196
MarketBeat's community ratings are surveys of what our community members think about Gritstone Oncology and other stocks. Vote "Outperform" if you believe GRTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: What are the FAANG Stocks?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel